# TAK catalysts: TAKEDA PHARMACEUTICAL CO LTD PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/tak/catalysts

> TAKEDA PHARMACEUTICAL CO LTD (TAK) has 105 upcoming catalysts. The next is the TAK-360 primary completion, November 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | TAKEDA PHARMACEUTICAL CO LTD |
| Ticker | TAK (NYSE) |
| SEC CIK | 1395064 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/tak |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| January 26, 2016 | [Dexilant Solutab (dexlansoprazole) FDA approval](https://sec-api.dev/pdufa/dexlansoprazole) | TAK |  | completed, approved | "NDA208056 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20160126, review_priority STANDARD; sponsor_name TAKEDA PHARMS USA; product DEXILANT SOLUTAB (DEXLANSOPRAZOLE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208056%22)) |
| January 28, 2017 | [Vyvanse (lisdexamfetamine dimesylate) FDA approval](https://sec-api.dev/pdufa/lisdexamfetamine) | TAK |  | completed, approved | "NDA208510 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20170128, review_priority STANDARD; sponsor_name TAKEDA PHARMS USA; product VYVANSE (LISDEXAMFETAMINE DIMESYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208510%22)) |
| April 28, 2017 | [ALUNBRIG (brigatinib) FDA approval](https://sec-api.dev/pdufa/brigatinib) | TAK |  | completed, approved | "NDA208772 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20170428, review_priority PRIORITY; sponsor_name TAKEDA PHARMS USA; product ALUNBRIG (BRIGATINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208772%22)) |
| June 20, 2017 | [Mydayis (amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate) FDA approval](https://sec-api.dev/pdufa/amphetamine-aspartate-amphetamine-dextroamphetamine-saccharate-dextroamphetamine) | TAK |  | completed, approved | "NDA022063 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20170620, review_priority STANDARD; sponsor_name TAKEDA PHARMS USA; product MYDAYIS (AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA022063%22)) |
| December 14, 2018 | [Motegrity (prucalopride succinate) FDA approval](https://sec-api.dev/pdufa/prucalopride) | TAK |  | completed, approved | "NDA210166 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20181214, review_priority STANDARD; sponsor_name TAKEDA PHARMS USA; product MOTEGRITY (PRUCALOPRIDE SUCCINATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210166%22)) |
| December 17, 2019 | [Entyvio® (vedolizumab) complete response letter (CRL)](https://sec-api.dev/pdufa/vedolizumab) | TAK |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22761133_2024_Orig1s000OtherActionLtrs.pdf%22)) |
| May 22, 2020 | [ALUNBRIG (brigatinib) label expansion decision](https://sec-api.dev/pdufa/brigatinib) | TAK |  | completed, approved | "NDA208772 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20200522, review_priority PRIORITY; sponsor_name TAKEDA PHARMS USA; product ALUNBRIG (BRIGATINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208772%22)) |
| June 26, 2020 | [Lialda (mesalamine) label expansion decision](https://sec-api.dev/pdufa/mesalamine) | TAK |  | completed, approved | "NDA022000 SUPPL-19 (Efficacy): submission_status AP, submission_status_date 20200626, review_priority STANDARD; sponsor_name TAKEDA PHARMS USA; product LIALDA (MESALAMINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA022000%22)) |
| November 13, 2020 | [Trintellix (vortioxetine hydrobromide) label expansion decision](https://sec-api.dev/pdufa/vortioxetine) | TAK |  | completed, approved | "NDA204447 SUPPL-20 (Efficacy): submission_status AP, submission_status_date 20201113, review_priority STANDARD; sponsor_name TAKEDA PHARMS USA; product TRINTELLIX (VORTIOXETINE HYDROBROMIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204447%22)) |
| December 18, 2020 | [Iclusig (ponatinib hydrochloride) label expansion decision](https://sec-api.dev/pdufa/ponatinib) | TAK |  | completed, approved | "NDA203469 SUPPL-34 (Efficacy): submission_status AP, submission_status_date 20201218, review_priority PRIORITY; sponsor_name TAKEDA PHARMS USA; product ICLUSIG (PONATINIB HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA203469%22)) |
| January 22, 2021 | [Trintellix (vortioxetine hydrobromide) label expansion decision](https://sec-api.dev/pdufa/vortioxetine) | TAK |  | completed, approved | "NDA204447 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20210122, review_priority PRIORITY; sponsor_name TAKEDA PHARMS USA; product TRINTELLIX (VORTIOXETINE HYDROBROMIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204447%22)) |
| July 29, 2021 | [Vyvanse (lisdexamfetamine dimesylate) label expansion decision](https://sec-api.dev/pdufa/lisdexamfetamine) | TAK |  | completed, approved | "NDA208510 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20210729, review_priority PRIORITY; sponsor_name TAKEDA PHARMS USA; product VYVANSE (LISDEXAMFETAMINE DIMESYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208510%22)) |
| September 15, 2021 | [Exkivity (mobocertinib succinate) FDA approval](https://sec-api.dev/pdufa/mobocertinib) | TAK |  | completed, approved | "NDA215310 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20210915, review_priority PRIORITY; sponsor_name TAKEDA PHARMS USA; product EXKIVITY (MOBOCERTINIB SUCCINATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215310%22)) |
| November 23, 2021 | [Livtencity (maribavir) FDA approval](https://sec-api.dev/pdufa/maribavir) | TAK |  | completed, approved | "NDA215596 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20211123, review_priority PRIORITY; sponsor_name TAKEDA PHARMS USA; product LIVTENCITY (MARIBAVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215596%22)) |
| December 17, 2021 | [Eohilia (budesonide) complete response letter (CRL)](https://sec-api.dev/pdufa/budesonide) | TAK |  | completed, complete response letter | "As such, we have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22213976_2024_Orig1s000OtherActionLtrs.pdf%22)) |
| February 15, 2022 | [Iclusig (ponatinib hydrochloride) label expansion decision](https://sec-api.dev/pdufa/ponatinib) | TAK |  | completed, approved | "NDA203469 SUPPL-35 (Efficacy): submission_status AP, submission_status_date 20220215, review_priority STANDARD; sponsor_name TAKEDA PHARMS USA; product ICLUSIG (PONATINIB HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA203469%22)) |
| February 28, 2022 | [ALUNBRIG (brigatinib) label expansion decision](https://sec-api.dev/pdufa/brigatinib) | TAK |  | completed, approved | "NDA208772 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20220228, review_priority STANDARD; sponsor_name TAKEDA PHARMS USA; product ALUNBRIG (BRIGATINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208772%22)) |
| April 28, 2022 | [Ninlaro (ixazomib citrate) label expansion decision](https://sec-api.dev/pdufa/ixazomib) | TAK |  | completed, approved | "NDA208462 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20220428, review_priority STANDARD; sponsor_name TAKEDA PHARMS USA; product NINLARO (IXAZOMIB CITRATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208462%22)) |
| January 25, 2023 | [Entyvio® (vedolizumab) label expansion decision](https://sec-api.dev/pdufa/vedolizumab) | TAK |  | completed, approved | "BLA125476 SUPPL-48 (Efficacy): submission_status AP, submission_status_date 20230125, review_priority STANDARD; sponsor_name TAKEDA PHARMS USA; product ENTYVIO (VEDOLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125476%22)) |
| July 27, 2023 | [Nesina (alogliptin benzoate) label expansion decision](https://sec-api.dev/pdufa/alogliptin-benzoate) | TAK |  | completed, approved | "NDA022271 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20230727, review_priority STANDARD; sponsor_name TAKEDA PHARMS USA; product NESINA (ALOGLIPTIN BENZOATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA022271%22)) |
| July 27, 2023 | [Kazano (alogliptin benzoate; metformin hydrochloride) label expansion decision](https://sec-api.dev/pdufa/alogliptin-benzoate-metformin) | TAK |  | completed, approved | "NDA203414 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20230727, review_priority STANDARD; sponsor_name TAKEDA PHARMS USA; product KAZANO (ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA203414%22)) |
| August 23, 2023 | [Trintellix (vortioxetine hydrobromide) label expansion decision](https://sec-api.dev/pdufa/vortioxetine) | TAK |  | completed, approved | "NDA204447 SUPPL-26 (Efficacy): submission_status AP, submission_status_date 20230823, review_priority PRIORITY; sponsor_name TAKEDA PHARMS USA; product TRINTELLIX (VORTIOXETINE HYDROBROMIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204447%22)) |
| September 27, 2023 | [Entyvio® (vedolizumab) FDA approval](https://sec-api.dev/pdufa/vedolizumab) | TAK |  | completed, approved | "BLA761133 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20230927, review_priority STANDARD; sponsor_name TAKEDA PHARMS USA; product ENTYVIO (VEDOLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761133%22)) |
| November 8, 2023 | [FRUZAQLA® (fruquintinib) FDA approval](https://sec-api.dev/pdufa/fruquintinib) | TAK | To treat refractory, metastatic colorectal cancer | completed, approved | "Fruzaqla \| fruquintinib \| 11/8/2023 \| To treat refractory, metastatic colorectal cancerDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)) |
| February 9, 2024 | [Eohilia (budesonide) FDA approval](https://sec-api.dev/pdufa/budesonide) | TAK |  | completed, approved | "NDA213976 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20240209, review_priority PRIORITY; sponsor_name TAKEDA PHARMS USA; product EOHILIA (BUDESONIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213976%22)) |
| March 19, 2024 | [Iclusig (ponatinib hydrochloride) label expansion decision](https://sec-api.dev/pdufa/ponatinib) | TAK |  | completed, approved | "NDA203469 SUPPL-37 (Efficacy): submission_status AP, submission_status_date 20240319, review_priority PRIORITY; sponsor_name TAKEDA PHARMS USA; product ICLUSIG (PONATINIB HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA203469%22)) |
| April 18, 2024 | [Entyvio® (vedolizumab) FDA approval](https://sec-api.dev/pdufa/vedolizumab) | TAK | moderately to severely active Crohn's disease | completed, approved | "BLA761359 ORIG-1 (Efficacy): submission_status AP, submission_status_date 20240418, review_priority STANDARD; sponsor_name TAKEDA PHARMS USA; product ENTYVIO (VEDOLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761359%22)) |
| March 3, 2025 | [MIMRYLO™ (rusfertide) topline data readout](https://sec-api.dev/pdufa/rusfertide) | TAK | Polycythemia Vera" | completed, positive | "The topline results of this study were announced on March 3, 2025, in "Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera"." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1395064/000139506425000164/form6k_120825.htm)) |
| March 18, 2025 | [TAK-771 topline data readout](https://sec-api.dev/pdufa/tak-771) | TAK |  | completed | "NCT05084053 (A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-28 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2025-03-18." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05084053?tab=results)) |
| May 5, 2025 | [Tdv primary completion](https://sec-api.dev/pdufa/tdv) | TAK | Healthy Volunteers | completed | "NCT06060067 (A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-05 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-05-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06060067)) |
| May 7, 2025 | [Darvadstrocel primary completion](https://sec-api.dev/pdufa/darvadstrocel) | TAK | Crohn's Disease; Complex Perianal Fistula | withdrawn | "NCT04701411 (A Study of Darvadstrocel for Treating Complex Perianal Fistulas in Children and Teenagers With Crohn's Disease): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-05-07 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2025-10-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04701411)) |
| May 30, 2025 | [Entyvio® (vedolizumab) primary completion](https://sec-api.dev/pdufa/vedolizumab) | TAK | Ulcerative Colitis; Crohn's Disease | completed | "NCT04738942 (A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-30 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-06-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04738942)) |
| Jun 2025 | [TAK-771 FDA approval](https://sec-api.dev/pdufa/tak-771) | TAK |  | completed, approved | "GAMMAGARD LIQUID ERC / Generic name: Immunoglobulin (IG) Infusion 10% (Human) (Low IgA) - In June 2025, Takeda announced that the U.S. Food and Drug Administration (FDA) approved GAMMAGARD LIQUID ERC with less than or equal to 2 µg/mL IgA in a 10% solution, the only ready-to-use liquid immunoglobulin (IG) therapy with low immunoglobulin A (IgA) content, as replacement therapy for people two years of age and older with primary immunodeficiency (PI)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395064/000139506426000162/noticeofconvocationofthe.htm)) |
| June 3, 2025 | [ORZEYFUL (oveporexton) primary completion](https://sec-api.dev/pdufa/oveporexton) | TAK | Narcolepsy Type 1 | completed | "NCT06470828 (A Study of TAK-861 for the Treatment of Narcolepsy Type 1): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-03 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-08-31." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06470828)) |
| June 4, 2025 | [TAK-861 primary completion](https://sec-api.dev/pdufa/tak-861) | TAK | Narcolepsy Type 1 | completed | "NCT06505031 (A Study of TAK-861 in People With Narcolepsy Type 1): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-04 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-07-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06505031)) |
| July 1, 2025 | [Entyvio® (vedolizumab) primary completion](https://sec-api.dev/pdufa/vedolizumab) | TAK | Colitis, Ulcerative | completed | "NCT04779307 (A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-01 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-04-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04779307)) |
| July 9, 2025 | [Tdv primary completion](https://sec-api.dev/pdufa/tdv) | TAK | Dengue Fever | completed | "NCT06741683 (A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2025-07-09 (ACTUAL); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06741683)) |
| July 10, 2025 | [Motegrity (prucalopride succinate) label expansion decision](https://sec-api.dev/pdufa/prucalopride) | TAK |  | completed, approved | "NDA210166 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20250710, review_priority STANDARD; sponsor_name TAKEDA PHARMS USA; product MOTEGRITY (PRUCALOPRIDE SUCCINATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210166%22)) |
| July 28, 2025 | [TAK-341 primary completion](https://sec-api.dev/pdufa/tak-341) | TAK | Multiple System Atrophy | completed | "NCT05526391 (A Study of TAK-341 in Treatment of Multiple System Atrophy): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-28 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-06-02." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05526391)) |
| July 30, 2025 | [Soticlestat primary completion](https://sec-api.dev/pdufa/soticlestat) | TAK | Epilepsy; Dravet Syndrome (DS); Lennox-Gastaut Syndrome (LGS) | withdrawn | "NCT03635073 (A Study of Soticlestat in Adults and Children With Rare Epilepsies): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-07-30 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-03-19." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03635073)) |
| Sep 2025 | [SHP677 label expansion decision](https://sec-api.dev/pdufa/shp677) | TAK |  | completed, approved | "-In September 2025, Takeda announced that the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (sBLA) for VONVENDI, expanding the indication to include routine prophylaxis to reduce the frequency of bleeding episodes in adults with VWD, including those with Type 1 and 2 disease, and on-demand and perioperative management of bleeding in pediatric patients with VWD." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1395064/000139506425000154/form6k-3_103025.htm)) |
| September 24, 2025 | [Soticlestat primary completion](https://sec-api.dev/pdufa/soticlestat) | TAK | Dravet Syndrome (DS); Lennox Gastaut Syndrome (LGS) | withdrawn | "NCT05163314 (A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-09-24 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-06-09." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05163314)) |
| October 10, 2025 | [Iclusig (ponatinib hydrochloride) label expansion decision](https://sec-api.dev/pdufa/ponatinib) | TAK |  | completed, approved | "NDA203469 SUPPL-38 (Efficacy): submission_status AP, submission_status_date 20251010, review_priority STANDARD; sponsor_name TAKEDA PHARMS USA; product ICLUSIG (PONATINIB HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA203469%22)) |
| October 17, 2025 | [TAK-279 primary completion](https://sec-api.dev/pdufa/tak-279) | TAK | Generalized Pustular Psoriasis; Erythrodermic Psoriasis | completed | "NCT06323356 (A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-17 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-11-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06323356)) |
| October 28, 2025 | [TAK-771 primary completion](https://sec-api.dev/pdufa/tak-771) | TAK |  | completed | "NCT05084053 (A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-28 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2025-03-18." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05084053)) |
| October 30, 2025 | [TAK-771 primary completion](https://sec-api.dev/pdufa/tak-771) | TAK | Primary Immunodeficiency Diseases (PID) | completed | "NCT05513586 (A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-30 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-05-19." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05513586)) |
| November 21, 2025 | [Livtencity (maribavir) label expansion decision](https://sec-api.dev/pdufa/maribavir) | TAK |  | completed, approved | "NDA215596 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20251121, review_priority STANDARD; sponsor_name TAKEDA PHARMS USA; product LIVTENCITY (MARIBAVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215596%22)) |
| December 9, 2025 | [TAK-101 primary completion](https://sec-api.dev/pdufa/tak-101) | TAK | Celiac Disease | completed | "NCT04530123 (Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-09 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-10-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04530123)) |
| December 18, 2025 | [Zasocitinib topline data readout](https://sec-api.dev/pdufa/zasocitinib) | TAK | moderate-to-severe plaque psoriasis | completed, positive | "OSAKA Japan AND CAMBRIDGE, Massachusetts, December 18, 2025 - Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the two pivotal Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1395064/000139506425000174/form6k_121825.htm)) |
| Jan 2026 | [Mirvetuximab NDA/BLA submission](https://sec-api.dev/pdufa/mirvetuximab) | TAK | folate receptor alpha | completed | "Development code: TAK-853 / Generic name: mirvetuximab soravtansine - In January 2026, Takeda announced it submitted the New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) for mirvetuximab soravtansine for the treatment of folate receptor alpha (FRα)-positive, platinum- resistant recurrent ovarian cancer (PROC) in Japan." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395064/000139506426000162/noticeofconvocationofthe.htm)) |
| January 20, 2026 | [TAK-881 primary completion](https://sec-api.dev/pdufa/tak-881) | TAK | Primary Immunodeficiency Diseases (PID) | completed | "NCT05755035 (A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2026-01-20 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-09-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05755035)) |
| Feb 2026 | [ORZEYFUL (oveporexton) NDA/BLA acceptance](https://sec-api.dev/pdufa/oveporexton) | TAK |  | completed | "Oveporexton was generally well-tolerated with a safety profile consistent across clinical studies to date. - In February 2026, Takeda announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton for the treatment of NT1." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395064/000139506426000162/noticeofconvocationofthe.htm)) |
| Mar 2026 | [MIMRYLO™ (rusfertide) NDA/BLA acceptance](https://sec-api.dev/pdufa/rusfertide) | TAK | with PV | completed | "- 45 - - In March 2026, Takeda and Protagonist Therapeutics announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) and granted Priority Review for rusfertide for the treatment of adults with PV." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395064/000139506426000162/noticeofconvocationofthe.htm)) |
| March 31, 2026 | [ORZEYFUL (oveporexton) NDA/BLA submission](https://sec-api.dev/pdufa/oveporexton) | TAK | excessive daytime sleepiness in NT1 | completed | "In the fiscal year ended March 31, 2026, we submitted New Drug Applications ("NDAs") in the U.S. for oveporexton and rusfertide following successful Phase 3 clinical trial results." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm)) |
| April 13, 2026 | [Dexilant Solutab (dexlansoprazole) primary completion](https://sec-api.dev/pdufa/dexlansoprazole) | TAK | Erosive Esophagitis | withdrawn | "NCT02615184 (A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-04-13 (ACTUAL); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02615184)) |
| April 16, 2026 | [TAK-755 primary completion](https://sec-api.dev/pdufa/tak-755) | TAK | Thrombotic Thrombocytopenic Purpura (TTP) | completed | "NCT05714969 (A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-04-16 (ACTUAL); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05714969)) |
| April 22, 2026 | [Zasocitinib primary completion](https://sec-api.dev/pdufa/zasocitinib) | TAK | Plaque Psoriasis | completed | "NCT06973291 (A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-22 (ACTUAL); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06973291)) |
| April 30, 2026 | [Entyvio® (vedolizumab) topline data readout](https://sec-api.dev/pdufa/vedolizumab) | TAK | Colitis, Ulcerative | completed | "NCT04779307 (A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-01 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-04-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04779307?tab=results)) |
| May 19, 2026 | [TAK-771 topline data readout](https://sec-api.dev/pdufa/tak-771) | TAK | Primary Immunodeficiency Diseases (PID) | completed | "NCT05513586 (A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-30 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-05-19." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05513586?tab=results)) |
| May 29, 2026 | [Tdv topline data readout](https://sec-api.dev/pdufa/tdv) | TAK | Healthy Volunteers | completed | "NCT06060067 (A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-05 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-05-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06060067?tab=results)) |
| June 2, 2026 | [TAK-341 topline data readout](https://sec-api.dev/pdufa/tak-341) | TAK | Multiple System Atrophy | completed | "NCT05526391 (A Study of TAK-341 in Treatment of Multiple System Atrophy): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-28 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-06-02." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05526391?tab=results)) |
| June 8, 2026 | [Entyvio® (vedolizumab) NDA/BLA acceptance](https://sec-api.dev/pdufa/vedolizumab) | TAK | moderately to severely active ulcerative colitis | completed | "On 8 June 2026, the Company announced that the FDA had accepted for review a BLA for" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184326003974/exh_993.htm)) |
| June 15, 2026 | [Entyvio® (vedolizumab) topline data readout](https://sec-api.dev/pdufa/vedolizumab) | TAK | Ulcerative Colitis; Crohn's Disease | completed | "NCT04738942 (A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-30 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-06-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04738942?tab=results)) |
| June 29, 2026 | [Tetravalent dengue vaccine (tdv) primary completion](https://sec-api.dev/pdufa/tetravalent-dengue-vaccine-tdv) | TAK | Dengue Fever | completed | "NCT07047521 (A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-29 (ACTUAL); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07047521)) |
| Q3 2026 | [MIMRYLO™ (rusfertide) PDUFA date](https://sec-api.dev/pdufa/rusfertide) | TAK |  | completed, approved | "The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395064/000139506426000162/noticeofconvocationofthe.htm)) |
| Q3 2026 | [ORZEYFUL (oveporexton) PDUFA date](https://sec-api.dev/pdufa/oveporexton) | TAK |  | completed, approved | "The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of calendar year 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395064/000139506426000162/noticeofconvocationofthe.htm)) |
| July 14, 2026 | [Zasocitinib primary completion](https://sec-api.dev/pdufa/zasocitinib) | TAK | Ulcerative Colitis | completed | "NCT06254950 (A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-07-14 (ACTUAL); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06254950)) |
| July 16, 2026 | [TAK-861 topline data readout](https://sec-api.dev/pdufa/tak-861) | TAK | Narcolepsy Type 1 | completed | "NCT06505031 (A Study of TAK-861 in People With Narcolepsy Type 1): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-04 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-07-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06505031?tab=results)) |
| July 21, 2026 | [Dexilant Solutab (dexlansoprazole) primary completion](https://sec-api.dev/pdufa/dexlansoprazole) | TAK | Gastroesophageal Reflux Disease (GERD) | completed | "NCT02616302 (A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-07-21 (ACTUAL); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02616302)) |
| July 22, 2026 | [Livtencity (maribavir) primary completion](https://sec-api.dev/pdufa/maribavir) | TAK | Cytomegalovirus (CMV) | completed | "NCT06439342 (A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-22 (ACTUAL); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06439342)) |
| August 5, 2026 | [ORZEYFUL (oveporexton) FDA approval](https://sec-api.dev/pdufa/oveporexton) | TAK | To treat narcolepsy type 1 | completed, approved | "Orzeyful \| oveporexton \| 8/5/2026 \| To treat narcolepsy type 1" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| August 28, 2026 | [MIMRYLO™ (rusfertide) FDA approval](https://sec-api.dev/pdufa/rusfertide) | TAK | To treat erythrocytosis in adults with polycythemia vera | completed, approved | "Mimrylo \| rusfertide \| 8/28/2026 \| To treat erythrocytosis in adults with polycythemia vera" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| August 31, 2026 | [ORZEYFUL (oveporexton) topline data readout](https://sec-api.dev/pdufa/oveporexton) | TAK | Narcolepsy Type 1 | completed | "NCT06470828 (A Study of TAK-861 for the Treatment of Narcolepsy Type 1): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-03 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-08-31." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06470828?tab=results)) |
| Sep 2026 | [Zasocitinib NDA/BLA acceptance](https://sec-api.dev/pdufa/zasocitinib) | TAK | with moderate-to-severe plaque psoriasis | completed | "-In September 2026, Takeda announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib for the treatment of adults with moderate-to-severe plaque psoriasis." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1395064/000139506426000345/form6k-2_102926.htm)) |
| September 22, 2026 | [Exkivity (mobocertinib succinate) primary completion](https://sec-api.dev/pdufa/mobocertinib) | TAK | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | "NCT04129502 (TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-22 (ACTUAL); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04129502)) |
| Sep to Dec 2026 | [Exkivity (mobocertinib succinate) topline data readout](https://sec-api.dev/pdufa/mobocertinib) | TAK | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | scheduled | "NCT04129502 (TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-22 (ACTUAL); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04129502)) |
| September 30, 2026 | [TAK-881 topline data readout](https://sec-api.dev/pdufa/tak-881) | TAK | Primary Immunodeficiency Diseases (PID) | completed | "NCT05755035 (A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2026-01-20 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-09-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05755035?tab=results)) |
| October 6, 2026 | [TAK-101 topline data readout](https://sec-api.dev/pdufa/tak-101) | TAK | Celiac Disease | completed | "NCT04530123 (Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-09 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-10-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04530123?tab=results)) |
| Nov 2026 to Feb 2027 | [TAK-360 topline data readout](https://sec-api.dev/pdufa/tak-360) | TAK | Idiopathic Hypersomnia | scheduled | "NCT06812078 (A Study of TAK-360 in Adults With Idiopathic Hypersomnia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06812078)) |
| Nov 2026 to Feb 2027 | [TAK-360 topline data readout](https://sec-api.dev/pdufa/tak-360) | TAK | Narcolepsy Type 2 | scheduled | "NCT06952699 (A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06952699)) |
| November 4, 2026 | [TAK-279 topline data readout](https://sec-api.dev/pdufa/tak-279) | TAK | Generalized Pustular Psoriasis; Erythrodermic Psoriasis | completed | "NCT06323356 (A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-17 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-11-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06323356?tab=results)) |
| November 2026 | [TAK-360 primary completion](https://sec-api.dev/pdufa/tak-360) | TAK | Idiopathic Hypersomnia | scheduled | "NCT06812078 (A Study of TAK-360 in Adults With Idiopathic Hypersomnia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06812078)) |
| November 2026 | [TAK-360 primary completion](https://sec-api.dev/pdufa/tak-360) | TAK | Narcolepsy Type 2 | scheduled | "NCT06952699 (A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06952699)) |
| Dec 2026 to Mar 2027 | [TAK-861 topline data readout](https://sec-api.dev/pdufa/tak-861) | TAK | Narcolepsy Type 1 (NT1); Narcolepsy With Cataplexy | scheduled | "NCT07363720 (A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-17 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07363720)) |
| December 2026 | [TAK-861 primary completion](https://sec-api.dev/pdufa/tak-861) | TAK | Narcolepsy Type 1 (NT1); Narcolepsy With Cataplexy | scheduled | "NCT07363720 (A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-17 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07363720)) |
| Q1 2027 | [Zasocitinib PDUFA date](https://sec-api.dev/pdufa/zasocitinib) | TAK |  | scheduled | "•The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1395064/000139506426000337/form6k_091426.htm)) |
| Jan to Apr 2027 | [Livtencity (maribavir) topline data readout](https://sec-api.dev/pdufa/maribavir) | TAK | Cytomegalovirus (CMV) | scheduled | "NCT05319353 (A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-18 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05319353)) |
| January 2027 | [Livtencity (maribavir) primary completion](https://sec-api.dev/pdufa/maribavir) | TAK | Cytomegalovirus (CMV) | scheduled | "NCT05319353 (A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-18 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05319353)) |
| Feb to May 2027 | [Zasocitinib topline data readout](https://sec-api.dev/pdufa/zasocitinib) | TAK | Crohn's Disease | scheduled | "NCT06233461 (A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02-17 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06233461)) |
| Feb to May 2027 | [Teduglutide topline data readout](https://sec-api.dev/pdufa/teduglutide) | TAK | Short Bowel Syndrome | scheduled | "NCT06973304 (A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-10 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06973304)) |
| Feb to May 2027 | [Zasocitinib (dose a) topline data readout](https://sec-api.dev/pdufa/zasocitinib-dose-a) | TAK | Hidradenitis Suppurativa | scheduled | "NCT07244263 (A Study of Zasocitinib in Adults With Hidradenitis Suppurativa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-05 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07244263)) |
| February 2027 | [Zasocitinib (dose a) primary completion](https://sec-api.dev/pdufa/zasocitinib-dose-a) | TAK | Hidradenitis Suppurativa | scheduled | "NCT07244263 (A Study of Zasocitinib in Adults With Hidradenitis Suppurativa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-05 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07244263)) |
| February 2027 | [Teduglutide primary completion](https://sec-api.dev/pdufa/teduglutide) | TAK | Short Bowel Syndrome | scheduled | "NCT06973304 (A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-10 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06973304)) |
| February 2027 | [Zasocitinib primary completion](https://sec-api.dev/pdufa/zasocitinib) | TAK | Crohn's Disease | scheduled | "NCT06233461 (A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02-17 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06233461)) |
| Mar to Jun 2027 | [TAK-755 topline data readout](https://sec-api.dev/pdufa/tak-755) | TAK | Thrombotic Thrombocytopenic Purpura (TTP) | scheduled | "NCT04683003 (A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-16 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04683003)) |
| Mar to Jun 2027 | [Zasocitinib topline data readout](https://sec-api.dev/pdufa/zasocitinib) | TAK | Nonsegmental Vitiligo | scheduled | "NCT07108283 (A Study of Zasocitinib in Adults With Nonsegmental Vitiligo): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03-26 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07108283)) |
| March 2027 | [TAK-755 primary completion](https://sec-api.dev/pdufa/tak-755) | TAK | Thrombotic Thrombocytopenic Purpura (TTP) | scheduled | "NCT04683003 (A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-16 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04683003)) |
| March 2027 | [Zasocitinib primary completion](https://sec-api.dev/pdufa/zasocitinib) | TAK | Nonsegmental Vitiligo | scheduled | "NCT07108283 (A Study of Zasocitinib in Adults With Nonsegmental Vitiligo): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03-26 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07108283)) |
| Apr to Jul 2027 | [Tdv topline data readout](https://sec-api.dev/pdufa/tdv) | TAK | Dengue Fever | scheduled | "NCT06579755 (A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-14 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06579755)) |
| April 2027 | [Tdv primary completion](https://sec-api.dev/pdufa/tdv) | TAK | Dengue Fever | scheduled | "NCT06579755 (A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-14 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06579755)) |
| May to Aug 2027 | [Zasocitinib topline data readout](https://sec-api.dev/pdufa/zasocitinib) | TAK | Psoriatic Arthritis | scheduled | "NCT06671483 (A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-18 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06671483)) |
| May to Aug 2027 | [Zasocitinib topline data readout](https://sec-api.dev/pdufa/zasocitinib) | TAK | Psoriatic Arthritis | scheduled | "NCT06671496 (A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-18 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06671496)) |
| May to Aug 2027 | [Zasocitinib topline data readout](https://sec-api.dev/pdufa/zasocitinib) | TAK | Palmoplantar Psoriasis | scheduled | "NCT07752108 (A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2027-05-30 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07752108)) |
| May 2027 | [Zasocitinib primary completion](https://sec-api.dev/pdufa/zasocitinib) | TAK | Psoriatic Arthritis | scheduled | "NCT06671483 (A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-18 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06671483)) |
| May 2027 | [Zasocitinib primary completion](https://sec-api.dev/pdufa/zasocitinib) | TAK | Psoriatic Arthritis | scheduled | "NCT06671496 (A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-18 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06671496)) |
| May 2027 | [Zasocitinib primary completion](https://sec-api.dev/pdufa/zasocitinib) | TAK | Palmoplantar Psoriasis | scheduled | "NCT07752108 (A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2027-05-30 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07752108)) |
| Jun to Sep 2027 | [Entyvio® (vedolizumab) topline data readout](https://sec-api.dev/pdufa/vedolizumab) | TAK | Crohn's Disease | scheduled | "NCT06227910 (A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-08 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06227910)) |
| June 2027 | [Entyvio® (vedolizumab) primary completion](https://sec-api.dev/pdufa/vedolizumab) | TAK | Crohn's Disease | scheduled | "NCT06227910 (A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-08 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06227910)) |
| Sep to Dec 2027 | [Vedolizumab iv topline data readout](https://sec-api.dev/pdufa/vedolizumab-iv) | TAK | Moderately to Severely Active Ulcerative Colitis | scheduled | "NCT03221036 (Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-24 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03221036)) |
| Sep to Dec 2027 | [Vedolizumab iv topline data readout](https://sec-api.dev/pdufa/vedolizumab-iv) | TAK | Crohn's Disease (CD) | scheduled | "NCT04779320 (A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-13 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04779320)) |
| September 2027 | [Vedolizumab iv primary completion](https://sec-api.dev/pdufa/vedolizumab-iv) | TAK | Crohn's Disease (CD) | scheduled | "NCT04779320 (A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-13 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04779320)) |
| September 2027 | [Vedolizumab iv primary completion](https://sec-api.dev/pdufa/vedolizumab-iv) | TAK | Moderately to Severely Active Ulcerative Colitis | scheduled | "NCT03221036 (Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-24 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03221036)) |
| Oct 2027 to Jan 2028 | [MIMRYLO™ (rusfertide) topline data readout](https://sec-api.dev/pdufa/rusfertide) | TAK | Polycythemia Vera | scheduled | "NCT07648030 (A Study of Rusfertide in Japanese Adults With Polycythemia Vera): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-28 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07648030)) |
| October 2027 | [MIMRYLO™ (rusfertide) primary completion](https://sec-api.dev/pdufa/rusfertide) | TAK | Polycythemia Vera | scheduled | "NCT07648030 (A Study of Rusfertide in Japanese Adults With Polycythemia Vera): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-28 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07648030)) |
| Nov 2027 to Feb 2028 | [Vonvendi topline data readout](https://sec-api.dev/pdufa/vonvendi) | TAK | Von Willebrand Disease (VWD) | scheduled | "NCT07129343 (A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-25 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07129343)) |
| Nov 2027 to Feb 2028 | [TAK-360 topline data readout](https://sec-api.dev/pdufa/tak-360) | TAK | Narcolepsy Type 1 | scheduled | "NCT07633301 (A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-28 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07633301)) |
| November 2027 | [Vonvendi primary completion](https://sec-api.dev/pdufa/vonvendi) | TAK | Von Willebrand Disease (VWD) | scheduled | "NCT07129343 (A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-25 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07129343)) |
| November 2027 | [TAK-360 primary completion](https://sec-api.dev/pdufa/tak-360) | TAK | Narcolepsy Type 1 | scheduled | "NCT07633301 (A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-28 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07633301)) |
| Dec 2027 to Mar 2028 | [Hypersialylated immune globulin g topline data readout](https://sec-api.dev/pdufa/hypersialylated-immune-globulin-g) | TAK | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | scheduled | "NCT06798012 (A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-02 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06798012)) |
| Dec 2027 to Mar 2028 | [TAK-755 topline data readout](https://sec-api.dev/pdufa/tak-755) | TAK | Acute Ischemic Stroke | scheduled | "NCT07392450 (A Study of TAK-755 in Adults With Acute Ischemic Stroke): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-06 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07392450)) |
| December 2027 | [Hypersialylated immune globulin g primary completion](https://sec-api.dev/pdufa/hypersialylated-immune-globulin-g) | TAK | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | scheduled | "NCT06798012 (A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-02 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06798012)) |
| December 2027 | [TAK-755 primary completion](https://sec-api.dev/pdufa/tak-755) | TAK | Acute Ischemic Stroke | scheduled | "NCT07392450 (A Study of TAK-755 in Adults With Acute Ischemic Stroke): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-06 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07392450)) |
| Feb to May 2028 | [Elritercept topline data readout](https://sec-api.dev/pdufa/elritercept) | TAK | Myelofibrosis | scheduled | "NCT05037760 (A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-28 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05037760)) |
| Feb to May 2028 | [TAK-861 topline data readout](https://sec-api.dev/pdufa/tak-861) | TAK | Narcolepsy Type 1 | scheduled | "NCT05816382 (A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-02-28 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05816382)) |
| February 2028 | [Elritercept primary completion](https://sec-api.dev/pdufa/elritercept) | TAK | Myelofibrosis | scheduled | "NCT05037760 (A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-28 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05037760)) |
| February 2028 | [TAK-861 primary completion](https://sec-api.dev/pdufa/tak-861) | TAK | Narcolepsy Type 1 | scheduled | "NCT05816382 (A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-02-28 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05816382)) |
| Mar to Jun 2028 | [Mezagitamab topline data readout](https://sec-api.dev/pdufa/mezagitamab) | TAK | Immune Thrombocytopenic Purpura (ITP) | scheduled | "NCT06722235 (A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-16 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06722235)) |
| Mar to Jun 2028 | [Zasocitinib topline data readout](https://sec-api.dev/pdufa/zasocitinib) | TAK | Crohn's Disease | scheduled | "NCT07403968 (A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-30 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07403968)) |
| March 2028 | [Mezagitamab primary completion](https://sec-api.dev/pdufa/mezagitamab) | TAK | Immune Thrombocytopenic Purpura (ITP) | scheduled | "NCT06722235 (A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-16 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06722235)) |
| March 2028 | [Zasocitinib primary completion](https://sec-api.dev/pdufa/zasocitinib) | TAK | Crohn's Disease | scheduled | "NCT07403968 (A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-30 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07403968)) |
| May to Aug 2028 | [TAK-881 topline data readout](https://sec-api.dev/pdufa/tak-881) | TAK | Primary Immunodeficiency Diseases (PID) | scheduled | "NCT06076642 (A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-05-16 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06076642)) |
| May to Aug 2028 | [Vedolizumab iv topline data readout](https://sec-api.dev/pdufa/vedolizumab-iv) | TAK | Ulcerative Colitis; Crohn's Disease | scheduled | "NCT06100289 (A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-16 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06100289)) |
| May 2028 | [TAK-881 primary completion](https://sec-api.dev/pdufa/tak-881) | TAK | Primary Immunodeficiency Diseases (PID) | scheduled | "NCT06076642 (A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-05-16 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06076642)) |
| May 2028 | [Vedolizumab iv primary completion](https://sec-api.dev/pdufa/vedolizumab-iv) | TAK | Ulcerative Colitis; Crohn's Disease | scheduled | "NCT06100289 (A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-16 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06100289)) |
| Jun to Sep 2028 | [TAK-881 topline data readout](https://sec-api.dev/pdufa/tak-881) | TAK | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | scheduled | "NCT06747351 (A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-25 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06747351)) |
| Jun to Sep 2028 | [Elritercept topline data readout](https://sec-api.dev/pdufa/elritercept) | TAK | Myelodysplastic Syndromes | scheduled | "NCT07319845 (A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06-26 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07319845)) |
| June 2028 | [TAK-881 primary completion](https://sec-api.dev/pdufa/tak-881) | TAK | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | scheduled | "NCT06747351 (A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-25 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06747351)) |
| June 2028 | [Elritercept primary completion](https://sec-api.dev/pdufa/elritercept) | TAK | Myelodysplastic Syndromes | scheduled | "NCT07319845 (A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06-26 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07319845)) |
| July 2028 | [MIMRYLO™ (rusfertide) primary completion](https://sec-api.dev/pdufa/rusfertide) | TAK | Polycythemia Vera | scheduled | "NCT07765602 (A Study of Rusfertide in Adults With Polycythemia Vera in China): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-07-01 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07765602)) |
| Jul to Oct 2028 | [MIMRYLO™ (rusfertide) topline data readout](https://sec-api.dev/pdufa/rusfertide) | TAK | Polycythemia Vera | scheduled | "NCT07765602 (A Study of Rusfertide in Adults With Polycythemia Vera in China): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-07-01 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07765602)) |
| Aug to Nov 2028 | [TAK-330 topline data readout](https://sec-api.dev/pdufa/tak-330) | TAK | Coagulation Disorder | scheduled | "NCT05156983 (A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-30 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05156983)) |
| Aug to Nov 2028 | [Fazirsiran topline data readout](https://sec-api.dev/pdufa/fazirsiran) | TAK | Alpha1-Antitrypsin Deficiency | scheduled | "NCT06165341 (Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-26 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06165341)) |
| August 2028 | [Fazirsiran primary completion](https://sec-api.dev/pdufa/fazirsiran) | TAK | Alpha1-Antitrypsin Deficiency | scheduled | "NCT06165341 (Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-26 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06165341)) |
| August 2028 | [TAK-330 primary completion](https://sec-api.dev/pdufa/tak-330) | TAK | Coagulation Disorder | scheduled | "NCT05156983 (A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-30 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05156983)) |
| Sep to Dec 2028 | [Elritercept topline data readout](https://sec-api.dev/pdufa/elritercept) | TAK | Myelodysplastic Syndromes | scheduled | "NCT06499285 (A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-15 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06499285)) |
| Sep to Dec 2028 | [Mezagitamab topline data readout](https://sec-api.dev/pdufa/mezagitamab) | TAK | Kidney Disease | scheduled | "NCT06963827 (A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-07 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06963827)) |
| Sep to Dec 2028 | [Igi, 10% topline data readout](https://sec-api.dev/pdufa/igi-10) | TAK | Multiple Myeloma; Secondary Immunodeficiency | scheduled | "NCT06980480 (A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-11 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06980480)) |
| September 2028 | [Mezagitamab primary completion](https://sec-api.dev/pdufa/mezagitamab) | TAK | Kidney Disease | scheduled | "NCT06963827 (A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-07 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06963827)) |
| September 2028 | [Igi, 10% primary completion](https://sec-api.dev/pdufa/igi-10) | TAK | Multiple Myeloma; Secondary Immunodeficiency | scheduled | "NCT06980480 (A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-11 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06980480)) |
| September 2028 | [Elritercept primary completion](https://sec-api.dev/pdufa/elritercept) | TAK | Myelodysplastic Syndromes | scheduled | "NCT06499285 (A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-15 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06499285)) |
| November 2028 | [TAK-928 primary completion](https://sec-api.dev/pdufa/tak-928) | TAK | IO Resistant Squamous and Nonsquamous NSCLC | scheduled | "NCT07217301 (A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-01 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07217301)) |
| Nov 2028 to Feb 2029 | [TAK-928 topline data readout](https://sec-api.dev/pdufa/tak-928) | TAK | IO Resistant Squamous and Nonsquamous NSCLC | scheduled | "NCT07217301 (A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-01 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07217301)) |
| Jan to Apr 2029 | [Fazirsiran topline data readout](https://sec-api.dev/pdufa/fazirsiran) | TAK | Alpha1-Antitrypsin Deficiency | scheduled | "NCT05677971 (Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-17 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05677971)) |
| January 2029 | [Idursulfase-it primary completion](https://sec-api.dev/pdufa/idursulfase-it) | TAK | Hunter Syndrome | scheduled | "NCT06031259 (Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-01-01 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06031259)) |
| Jan to Apr 2029 | [Idursulfase-it topline data readout](https://sec-api.dev/pdufa/idursulfase-it) | TAK | Hunter Syndrome | scheduled | "NCT06031259 (Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-01-01 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06031259)) |
| Jan to Apr 2029 | [Mezagitamab topline data readout](https://sec-api.dev/pdufa/mezagitamab) | TAK | Antibody-Mediated Rejection (AMR) | scheduled | "NCT07613359 (A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01-15 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07613359)) |
| January 2029 | [Mezagitamab primary completion](https://sec-api.dev/pdufa/mezagitamab) | TAK | Antibody-Mediated Rejection (AMR) | scheduled | "NCT07613359 (A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01-15 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07613359)) |
| January 2029 | [Fazirsiran primary completion](https://sec-api.dev/pdufa/fazirsiran) | TAK | Alpha1-Antitrypsin Deficiency | scheduled | "NCT05677971 (Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-17 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05677971)) |
| Apr to Jul 2029 | [Elritercept topline data readout](https://sec-api.dev/pdufa/elritercept) | TAK | Myelodysplastic Syndrome; Anemia | scheduled | "NCT07422480 (A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04-30 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07422480)) |
| April 2029 | [Elritercept primary completion](https://sec-api.dev/pdufa/elritercept) | TAK | Myelodysplastic Syndrome; Anemia | scheduled | "NCT07422480 (A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04-30 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07422480)) |
| Jul to Oct 2029 | [Mezagitamab topline data readout](https://sec-api.dev/pdufa/mezagitamab) | TAK | Immune Thrombocytopenic Purpura (ITP) | scheduled | "NCT06948318 (A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-29 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06948318)) |
| July 2029 | [Mezagitamab primary completion](https://sec-api.dev/pdufa/mezagitamab) | TAK | Immune Thrombocytopenic Purpura (ITP) | scheduled | "NCT06948318 (A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-29 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06948318)) |
| Aug to Nov 2029 | [TAK-279 topline data readout](https://sec-api.dev/pdufa/tak-279) | TAK | Plaque Psoriasis | scheduled | "NCT06550076 (A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-08-05 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06550076)) |
| August 2029 | [TAK-279 primary completion](https://sec-api.dev/pdufa/tak-279) | TAK | Plaque Psoriasis | scheduled | "NCT06550076 (A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-08-05 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06550076)) |
| Sep to Dec 2029 | [Trintellix (vortioxetine hydrobromide) topline data readout](https://sec-api.dev/pdufa/vortioxetine) | TAK | Major Depressive Disorder | scheduled | "NCT07204314 (A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-30 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07204314)) |
| September 2029 | [Trintellix (vortioxetine hydrobromide) primary completion](https://sec-api.dev/pdufa/vortioxetine) | TAK | Major Depressive Disorder | scheduled | "NCT07204314 (A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-30 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07204314)) |
| Oct 2029 to Jan 2030 | [Elritercept topline data readout](https://sec-api.dev/pdufa/elritercept) | TAK | Myelodysplastic Syndromes; Cytopenia | scheduled | "NCT04419649 (A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-10-30 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04419649)) |
| October 2029 | [Elritercept primary completion](https://sec-api.dev/pdufa/elritercept) | TAK | Myelodysplastic Syndromes; Cytopenia | scheduled | "NCT04419649 (A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-10-30 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04419649)) |
| Dec 2029 to Mar 2030 | [Zasocitinib topline data readout](https://sec-api.dev/pdufa/zasocitinib) | TAK | Crohn's Disease; Ulcerative Colitis | scheduled | "NCT06764615 (A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-12-30 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06764615)) |
| Dec 2029 to Mar 2030 | [Zasocitinib topline data readout](https://sec-api.dev/pdufa/zasocitinib) | TAK | Psoriatic Arthritis | scheduled | "NCT07286058 (Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-18 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07286058)) |
| Dec 2029 to Mar 2030 | [Elritercept topline data readout](https://sec-api.dev/pdufa/elritercept) | TAK | Myelofibrosis; Anemia | scheduled | "NCT07623161 (A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-07 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07623161)) |
| December 2029 | [Elritercept primary completion](https://sec-api.dev/pdufa/elritercept) | TAK | Myelofibrosis; Anemia | scheduled | "NCT07623161 (A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-07 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07623161)) |
| December 2029 | [Zasocitinib primary completion](https://sec-api.dev/pdufa/zasocitinib) | TAK | Psoriatic Arthritis | scheduled | "NCT07286058 (Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-18 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07286058)) |
| December 2029 | [Zasocitinib primary completion](https://sec-api.dev/pdufa/zasocitinib) | TAK | Crohn's Disease; Ulcerative Colitis | scheduled | "NCT06764615 (A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-12-30 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06764615)) |
| Jan to Apr 2030 | [Entyvio® (vedolizumab) topline data readout](https://sec-api.dev/pdufa/vedolizumab) | TAK | Pouchitis | scheduled | "NCT06443502 (A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-01-31 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06443502)) |
| January 2030 | [Entyvio® (vedolizumab) primary completion](https://sec-api.dev/pdufa/vedolizumab) | TAK | Pouchitis | scheduled | "NCT06443502 (A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-01-31 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06443502)) |
| Mar to Jun 2030 | [Vedolizumab iv topline data readout](https://sec-api.dev/pdufa/vedolizumab-iv) | TAK | Crohn's Disease | scheduled | "NCT05837897 (A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-03-08 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05837897)) |
| Mar to Jun 2030 | [Tdv topline data readout](https://sec-api.dev/pdufa/tdv) | TAK | Dengue Fever | scheduled | "NCT06665035 (A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-03-03 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06665035)) |
| March 2030 | [Tdv primary completion](https://sec-api.dev/pdufa/tdv) | TAK | Dengue Fever | scheduled | "NCT06665035 (A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-03-03 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06665035)) |
| March 2030 | [Vedolizumab iv primary completion](https://sec-api.dev/pdufa/vedolizumab-iv) | TAK | Crohn's Disease | scheduled | "NCT05837897 (A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-03-08 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05837897)) |
| Apr to Jul 2030 | [Vonicog alfa topline data readout](https://sec-api.dev/pdufa/vonicog-alfa) | TAK | Von Willebrand Disease (VWD) | scheduled | "NCT05582993 (A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-04-11 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05582993)) |
| Apr to Jul 2030 | [Zasocitinib topline data readout](https://sec-api.dev/pdufa/zasocitinib) | TAK | Psoriatic Arthritis | scheduled | "NCT07871721 (A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-04-18 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07871721)) |
| April 2030 | [Vonicog alfa primary completion](https://sec-api.dev/pdufa/vonicog-alfa) | TAK | Von Willebrand Disease (VWD) | scheduled | "NCT05582993 (A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-04-11 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05582993)) |
| April 2030 | [Zasocitinib primary completion](https://sec-api.dev/pdufa/zasocitinib) | TAK | Psoriatic Arthritis | scheduled | "NCT07871721 (A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-04-18 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07871721)) |
| Aug to Nov 2030 | [Vedolizumab sc topline data readout](https://sec-api.dev/pdufa/vedolizumab-sc) | TAK | Ulcerative Colitis; Crohn's Disease | scheduled | "NCT06405087 (A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-08-12 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06405087)) |
| August 2030 | [Vedolizumab sc primary completion](https://sec-api.dev/pdufa/vedolizumab-sc) | TAK | Ulcerative Colitis; Crohn's Disease | scheduled | "NCT06405087 (A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-08-12 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06405087)) |

## Drugs

- [Nesina (alogliptin benzoate)](https://sec-api.dev/pdufa/alogliptin-benzoate): 
- [Kazano (alogliptin benzoate; metformin hydrochloride)](https://sec-api.dev/pdufa/alogliptin-benzoate-metformin): 
- [Mydayis (amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate)](https://sec-api.dev/pdufa/amphetamine-aspartate-amphetamine-dextroamphetamine-saccharate-dextroamphetamine): 
- [ALUNBRIG (brigatinib)](https://sec-api.dev/pdufa/brigatinib): 
- [Eohilia (budesonide)](https://sec-api.dev/pdufa/budesonide): 
- [Darvadstrocel](https://sec-api.dev/pdufa/darvadstrocel): Crohn's Disease
- [Dexilant Solutab (dexlansoprazole)](https://sec-api.dev/pdufa/dexlansoprazole): Erosive Esophagitis, Gastroesophageal Reflux Disease (GERD)
- [Elritercept](https://sec-api.dev/pdufa/elritercept): very low-, low-, or intermediate-risk mds, wide range of patients with disorders, lower-risk mds in december 2024, Myelofibrosis, Myelodysplastic Syndromes, Myelodysplastic Syndrome
- [Fazirsiran](https://sec-api.dev/pdufa/fazirsiran): Alpha1-Antitrypsin Deficiency
- [FRUZAQLA® (fruquintinib)](https://sec-api.dev/pdufa/fruquintinib): To treat refractory, metastatic colorectal cancer
- [Hypersialylated immune globulin g](https://sec-api.dev/pdufa/hypersialylated-immune-globulin-g): Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- [Idursulfase-it](https://sec-api.dev/pdufa/idursulfase-it): Hunter Syndrome
- [Igi, 10%](https://sec-api.dev/pdufa/igi-10): Multiple Myeloma
- [Ninlaro (ixazomib citrate)](https://sec-api.dev/pdufa/ixazomib): 
- [Vyvanse (lisdexamfetamine dimesylate)](https://sec-api.dev/pdufa/lisdexamfetamine): 
- [Livtencity (maribavir)](https://sec-api.dev/pdufa/maribavir): Cytomegalovirus (CMV)
- [Lialda (mesalamine)](https://sec-api.dev/pdufa/mesalamine): 
- [Mezagitamab](https://sec-api.dev/pdufa/mezagitamab): Kidney Disease, Antibody-Mediated Rejection (AMR), Immune Thrombocytopenic Purpura (ITP)
- [Mirvetuximab](https://sec-api.dev/pdufa/mirvetuximab): folate receptor alpha
- [Exkivity (mobocertinib succinate)](https://sec-api.dev/pdufa/mobocertinib): Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- [ORZEYFUL (oveporexton)](https://sec-api.dev/pdufa/oveporexton): nt1 in adult patients, narcolepsy type 1, excessive daytime sleepiness in nt1, To treat narcolepsy type 1
- [Iclusig (ponatinib hydrochloride)](https://sec-api.dev/pdufa/ponatinib): 
- [Motegrity (prucalopride succinate)](https://sec-api.dev/pdufa/prucalopride): 
- [MIMRYLO™ (rusfertide)](https://sec-api.dev/pdufa/rusfertide): erythrocytosis in adults with polycythemia vera, polycythemia vera", with pv, polycythemia vera, To treat erythrocytosis in adults with polycythemia vera
- [SHP677](https://sec-api.dev/pdufa/shp677): 
- [Soticlestat](https://sec-api.dev/pdufa/soticlestat): Epilepsy, Dravet Syndrome (DS)
- [TAK-101](https://sec-api.dev/pdufa/tak-101): Celiac Disease
- [TAK-279](https://sec-api.dev/pdufa/tak-279): Plaque Psoriasis, Generalized Pustular Psoriasis
- [TAK-330](https://sec-api.dev/pdufa/tak-330): Coagulation Disorder
- [TAK-341](https://sec-api.dev/pdufa/tak-341): Multiple System Atrophy
- [TAK-360](https://sec-api.dev/pdufa/tak-360): Narcolepsy Type 1, Idiopathic Hypersomnia, Narcolepsy Type 2
- [TAK-755](https://sec-api.dev/pdufa/tak-755): Thrombotic Thrombocytopenic Purpura (TTP), Acute Ischemic Stroke
- [TAK-771](https://sec-api.dev/pdufa/tak-771): Primary Immunodeficiency Diseases (PID), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- [TAK-861](https://sec-api.dev/pdufa/tak-861): Narcolepsy Type 1 (NT1), Narcolepsy Type 1
- [TAK-881](https://sec-api.dev/pdufa/tak-881): Primary Immunodeficiency Diseases (PID), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- [TAK-928](https://sec-api.dev/pdufa/tak-928): IO Resistant Squamous and Nonsquamous NSCLC
- [Tdv](https://sec-api.dev/pdufa/tdv): Healthy Volunteers, Dengue Fever
- [Teduglutide](https://sec-api.dev/pdufa/teduglutide): Short Bowel Syndrome
- [Tetravalent dengue vaccine (tdv)](https://sec-api.dev/pdufa/tetravalent-dengue-vaccine-tdv): Dengue Fever
- [Entyvio® (vedolizumab)](https://sec-api.dev/pdufa/vedolizumab): moderately to severely active ulcerative colitis, moderately to severely active crohn's disease, Pouchitis, Colitis, Ulcerative, Ulcerative Colitis, Crohn's Disease
- [Vedolizumab iv](https://sec-api.dev/pdufa/vedolizumab-iv): Crohn's Disease, Ulcerative Colitis, Crohn's Disease (CD), Moderately to Severely Active Ulcerative Colitis
- [Vedolizumab sc](https://sec-api.dev/pdufa/vedolizumab-sc): Ulcerative Colitis
- [Vonicog alfa](https://sec-api.dev/pdufa/vonicog-alfa): Von Willebrand Disease (VWD)
- [Vonvendi](https://sec-api.dev/pdufa/vonvendi): Von Willebrand Disease (VWD)
- [Trintellix (vortioxetine hydrobromide)](https://sec-api.dev/pdufa/vortioxetine): Major Depressive Disorder
- [Zasocitinib](https://sec-api.dev/pdufa/zasocitinib): moderate-to-severe plaque psoriasis, with moderate-to-severe plaque psoriasis, Psoriatic Arthritis, Nonsegmental Vitiligo, Ulcerative Colitis, Crohn's Disease, Palmoplantar Psoriasis, Plaque Psoriasis
- [Zasocitinib (dose a)](https://sec-api.dev/pdufa/zasocitinib-dose-a): Hidradenitis Suppurativa

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/tak/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TAK catalysts: TAKEDA PHARMACEUTICAL CO LTD PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/tak/catalysts

```bibtex
@misc{secapidev_companies_tak_catalysts_20261116,
  title        = {TAK catalysts: TAKEDA PHARMACEUTICAL CO LTD PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/tak/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_tak_catalysts_20261116","title":"TAK catalysts: TAKEDA PHARMACEUTICAL CO LTD PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/tak/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
